Mostrar el registro sencillo del ítem

dc.contributor.authorLopez-de la Rosa, Alberto
dc.contributor.authorTelleria, Juan J
dc.contributor.authorPosada De la Paz, Manuel 
dc.contributor.authorHermosilla-Gimeno, Isabel 
dc.contributor.authorAgurtzane Rivas, Miren
dc.contributor.authorGilabert, Raúl
dc.contributor.authorCoco-Martín, Rosa M
dc.date.accessioned2024-07-12T12:26:53Z
dc.date.available2024-07-12T12:26:53Z
dc.date.issued2024-06-13
dc.identifier.citationOrphanet J Rare Dis. 2024 Jun 13;19(1):234.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/20545
dc.descriptionAccess to data in the registry itself is available to authorized users under conditions governed by the registry data access policy set out on the registry website at https://registroraras.isciii.es/Comun/Inicio.aspx. The data protection policy according to GRDP standards of the RePER registry can be found in: https://www.isciii.es/InformacionCiudadanos/_layouts/15/WopiFrame.aspx?sourcedoc=%7B22A0BEC5-​A52D-​4375-​BEBF-​D10AC1C2D133%7D&fle=Politica_Privacidad_ISCIII.pdf&action=default. Owing to intellectual property restrictions, the full registry codebook is not publicly available but, is available from the responsible staf of the registry on a reasonable request, subject to certain conditions restricting commercial use.es_ES
dc.description.abstractBackground: The low prevalence of rare diseases poses a significant challenge in advancing their understanding. This study aims to delineate the clinical and genetic characteristics of patients with rare eye diseases (RED) enrolled in the Spanish Rare Diseases Patient Registry. Methods: A total of 864 patients from the registry database were included. Diseases were categorized into inherited retinal dystrophies (n=688); anterior segment diseases (n=48); congenital malformations (n=27); and syndromic diseases with ocular involvement including muscular (n=46), neurological (n=34), or metabolic (n=13); inflammatory diseases (n=4); and tumors (n=4). Data on visual acuity (VA) and/or visual field (VF), symptoms and signs, concurrent diseases in syndromic cases, age of onset and at diagnosis, affected genes, disability rating, inability to work and dependency grade recognition were collected. Results: A mean diagnostic delay of 7 years from symptom onset was observed. Commonly reported symptoms included photophobia, night blindness, and progressive vision loss (≥57% of patients). Cataract was the most prevalent secondary disease (46%), with pseudophakia being the most common ocular surgery (26%). Hearing loss and cardiovascular diseases were the most prevalent concurrent systemic diseases (≥13%). Certificates of disability, incapacity for work, and dependency were held by 87%, 42%, and 19% of patients, respectively. Among the 719 patients with available VA data, 193 (27%) were blind, and 188 (26%) had moderate to severe visual impairment. Over half of the patients (54%) exhibited VF defects, and 216 (25%) had concentric contraction ≤5° or abolished VF. Most had genetic diseases with autosomal recessive (55%), autosomal dominant (30%), X-linked (9%), and mitochondrial (6%) patterns. One patient had mutations in both recessive USH2A and dominant RHO genes simultaneously. Of the 656 patients (75.7%) who underwent genetic testing, only 461 (70.3%) received a positive result (pathogenic or likely pathogenic mutations explaining the phenotype). We found 62 new gene variants related to RED not previously reported in databases of genetic variants related to specific phenotypes. Conclusions: This study delineates the clinical and genotypic profiles of RED in Spain. Genetic diseases, particularly retinal disorders, predominate, but a significant proportion of affected patients remain genetically undiagnosed, hindering potential gene therapy endeavors. Despite notable improvements in reducing diagnosis delays, it is still remarkable. RED frequently lead to disability and blindness among young populations.es_ES
dc.description.sponsorshipNovartis Pharmaceutical SA funded the Chair of Retinal Dystrophies and Degenerations of the University of Valladolid in 2021 and 2022 and also collaborated fnancially with ONERO.es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectClinicales_ES
dc.subjectGenetices_ES
dc.subjectRare diseaseses_ES
dc.subjectEyees_ES
dc.subjectOculares_ES
dc.subjectRegistryes_ES
dc.subjectSpaines_ES
dc.subject.meshEye Diseases es_ES
dc.subject.meshRegistries es_ES
dc.subject.meshRare Diseases es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshFemale es_ES
dc.subject.meshSpain es_ES
dc.subject.meshAdult es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshChild es_ES
dc.subject.meshYoung Adult es_ES
dc.subject.meshChild, Preschool es_ES
dc.subject.meshAged es_ES
dc.subject.meshInfant es_ES
dc.subject.meshVisual Acuity es_ES
dc.subject.meshRetinal Dystrophies es_ES
dc.titleClinical and genetic characterization of patients with eye diseases included in the Spanish Rare Diseases Patient Registryes_ES
dc.typeresearch articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID38872169es_ES
dc.format.volume19es_ES
dc.format.number1es_ES
dc.format.page234es_ES
dc.identifier.doi10.1186/s13023-024-03242-6es_ES
dc.contributor.funderNovartis es_ES
dc.contributor.funderUniversidad de Valladolid (España)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1750-1172es_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s13023-024-03242-6es_ES
dc.identifier.journalOrphanet journal of rare diseaseses_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional